Lista de obras -

2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients

scholarly article by Hana M El Sahly et al published November 2018 in Open Forum Infectious Diseases

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

artículo científico publicado en 2007

A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route

artículo científico publicado en 2009

Adjuvants for pandemic influenza vaccines.

artículo científico publicado en 2009

Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination

artículo científico publicado en 2005

Antibody quantity versus quality after influenza vaccination

artículo científico publicado en 2009

Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).

artículo científico publicado en 2006

Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine

artículo científico publicado en 2015

Challenges Remain for Influenza Vaccination of Children

artículo científico publicado en 2016

Clinical data on Fluarix: an inactivated split seasonal influenza vaccine

artículo científico publicado en 2008

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects

artículo científico publicado en 2015

Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans

artículo científico publicado en 2009

Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes ⬇️

artículo científico publicado el 13 de agosto de 2012

Domain specificity of the human antibody response to Bacillus anthracis protective antigen

artículo científico publicado en 2008

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

artículo científico publicado en 2009

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial

artículo científico publicado en 2015

Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial

artículo científico publicado en 2013

Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial

artículo científico

Effects of infection and disease with Mycobacterium tuberculosison serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen ⬇️

artículo científico publicado el 19 de junio de 2013

Efficacy of an acellular pertussis vaccine among adolescents and adults.

artículo científico publicado en 2005

Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy

artículo científico publicado en 2003

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults

artículo científico publicado en 2009

Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults

artículo científico publicado en 2002

Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine ⬇️

artículo científico publicado el 22 de agosto de 2011

Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human

artículo científico publicado en 2014

Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies

artículo científico publicado en 2016

Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed

artículo científico publicado en 2009

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses

artículo científico publicado en 2008

Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial

artículo científico publicado en 2012

Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans

artículo científico publicado en 2016

Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study

artículo científico publicado en 2004

Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women

artículo científico publicado en 2011

Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine

scientific article published on 02 June 2008

Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination

artículo científico publicado en 2007

Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria

artículo científico publicado en 2002

Influenza A(H5N1) vaccines: are we better prepared for the next pandemic?

artículo científico publicado en 2013

Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here?

artículo científico publicado en 2015

Intanza®: a new intradermal vaccine for seasonal influenza ⬇️

artículo científico publicado el 1 de diciembre de 2010

Multiple Epstein-Barr Virus Infections in Healthy Individuals ⬇️

artículo científico publicado el 1 de junio de 2003

Pandemic H5N1 influenza vaccine development: an update.

artículo científico publicado en 2008

Paratope diversity in the human antibody response to Bacillus anthracis protective antigen

artículo científico publicado en 2007

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

artículo científico publicado en 2015

Perspectives on human microbiome research ethics

artículo científico publicado en 2012

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations

artículo científico publicado en 2014

Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy.

artículo científico publicado en 2003

Prenatal passive transfer of maternal immunity in Asian elephants (Elephas maximus) ⬇️

artículo científico publicado el 26 de marzo de 2013

Preparing for a possible pandemic: influenza A/H5N1 vaccine development.

artículo científico publicado en 2007

Prevalence of Antibody to Bordetella pertussis Antigens in Serum Specimens Obtained from 1793 Adolescents and Adults

scientific article published in 2004

Progress in the Diagnosis, Prevention, and Treatment of Pertussis

artículo científico publicado en 2003

Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease

scientific article published on 19 September 2016

Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

artículo científico publicado en 2017

Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines ⬇️

artículo científico publicado el 26 de octubre de 2012

Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised).

artículo científico publicado en 2013

Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine

artículo científico publicado en 2006

Repeated immunization of children with inactivated and live attenuated influenza virus vaccines: safety, immunogenicity, and protective efficacy

artículo científico publicado en 2002

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.

artículo científico publicado en 2015

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old

artículo científico publicado en 2015

Safety and immunogenicity of a candidate parvovirus B19 vaccine ⬇️

artículo científico publicado el 30 de julio de 2011

Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial

artículo científico

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

artículo científico publicado en 2009

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

artículo científico publicado en 2008

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

artículo científico publicado en 2009

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

artículo científico publicado en 2006

Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons

article

Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster ⬇️

artículo científico publicado el 30 de abril de 2013

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant

artículo científico publicado en 2014

The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters ⬇️

artículo científico publicado el 19 de noviembre de 2012

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial

artículo científico publicado en 2017

Vaccines for pandemic influenza: summary of recent clinical trials.

artículo científico publicado en 2009

Lista de obras de

2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route

Adjuvants for pandemic influenza vaccines.

Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination

Antibody quantity versus quality after influenza vaccination

Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).

Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine

Challenges Remain for Influenza Vaccination of Children

Clinical data on Fluarix: an inactivated split seasonal influenza vaccine

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects

Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans

Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes ⬇️

Domain specificity of the human antibody response to Bacillus anthracis protective antigen

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial

Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial

Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial

Effects of infection and disease with Mycobacterium tuberculosison serum antibody to glucan and arabinomannan: two surface polysaccharides of this pathogen ⬇️

Efficacy of an acellular pertussis vaccine among adolescents and adults.

Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults

Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults

Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine ⬇️

Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human

Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies

Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses

Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial

Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans

Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study

Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women

Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine

Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination

Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria

Influenza A(H5N1) vaccines: are we better prepared for the next pandemic?

Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here?

Intanza®: a new intradermal vaccine for seasonal influenza ⬇️

Multiple Epstein-Barr Virus Infections in Healthy Individuals ⬇️

Pandemic H5N1 influenza vaccine development: an update.

Paratope diversity in the human antibody response to Bacillus anthracis protective antigen

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

Perspectives on human microbiome research ethics

Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations

Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy.

Prenatal passive transfer of maternal immunity in Asian elephants (Elephas maximus) ⬇️

Preparing for a possible pandemic: influenza A/H5N1 vaccine development.

Prevalence of Antibody to Bordetella pertussis Antigens in Serum Specimens Obtained from 1793 Adolescents and Adults

Progress in the Diagnosis, Prevention, and Treatment of Pertussis

Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease

Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines ⬇️

Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised).

Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine

Repeated immunization of children with inactivated and live attenuated influenza virus vaccines: safety, immunogenicity, and protective efficacy

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old

Safety and immunogenicity of a candidate parvovirus B19 vaccine ⬇️

Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons

Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster ⬇️

Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant

The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters ⬇️

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial

Vaccines for pandemic influenza: summary of recent clinical trials.

Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine